PPIs: Most potent, irreversible, slow onset (prodrug) Hβ blockers: Less potent, reversible, faster onset Cimetidine: CYP inhibitor + antiandrogen (gynecomastia)
LO 1 β P-CABs
What are P-CABs? Example and advantage?
Answer
P-CABs: KβΊ-competitive antagonists (vonoprazan) Mechanism: Reversible, faster onset/offset than PPIs Advantage: More predictable pharmacokinetics
LO 2 β H. pylori Therapy
Quadruple vs. Triple β when preferred?
Answer
Quadruple (PPI+Bi+Metro+Tet): Preferred in clarithromycin-resistant areas Triple (PPI+Clarith+Amox): Older, less effective now Confirm: Urea breath or stool antigen 4 weeks post-Rx
How does it work and why co-dosing timing matters?
Answer
Mechanism: Polymerizes in acidic environment β sticky gel binds ulcer CRITICAL: Requires acidic pH β do NOT give with PPIs/Hβ blockers simultaneously Dosing: 1h before meals, separate timing
Drill 1: Laxative Onset Times (Fastest to Slowest)
Drag to arrange laxatives by speed of action
Osmotic (lactulose, PEG) β hours
Stimulant (senna, bisacodyl) β 6-12 hrs
Bulk (psyllium) β 1-3 days
Stool softener (docusate) β days
Osmotic (hours)
Stimulant (6-12 hrs)
Bulk (1-3 days)
Stool softener (days)
Drill 2: H. pylori Eradication Steps
Order quadruple therapy components in typical regimen sequence
PPI (omeprazole) + Bismuth subsalicylate daily
Add metronidazole (first-line for resistance)
Add tetracycline (covers resistant strains)
Confirm eradication 4+ weeks post-treatment
PPI + Bismuth daily
Add metronidazole
Add tetracycline
Confirm eradication 4+ weeks later
Drill 3: Vomiting Reflex Pathway (Stimulus to Response)
Order components of the vomiting reflex arc for chemotherapy
GI damage from chemotherapy
Enterochromaffin cells release 5-HT
Vagal afferents (5-HTβ receptors) β NTS
NTS coordinates vomiting reflex
Emesis (vomiting)
GI damage from chemo
5-HT release
Vagal afferents β NTS
NTS coordinates
Emesis
Drill 4: IBD Therapy Escalation (Mild to Severe)
Arrange IBD treatments from first-line to last resort
5-ASA (mesalamine) β first-line UC
Corticosteroids (budesonide) β induction
Immunomodulators (azathioprine)
Anti-TNF (infliximab/adalimumab)
Newer biologics (vedolizumab/risankizumab)
5-ASA first-line
Corticosteroids
Immunomodulators
Anti-TNF
Newer biologics
Drill 5: PPI/Hβ Blocker Mechanism Hierarchy
Rank acid suppression targets from "most upstream" to "most downstream" in parietal cell
Mβ muscarinic (ACh) β vagal input
Gastrin/CCK-B receptors
Hβ receptors (histamine)
HβΊ/KβΊ-ATPase pump β final step
Mβ muscarinic
Gastrin/CCK-B
Hβ receptors
HβΊ/KβΊ-ATPase (final)
Step 1-Style MCQs: Select the best answer. Correct = green, incorrect = red.
MCQ 1 β Acid Suppression Potency
A patient with GERD is started on omeprazole. Compared to ranitidine (Hβ blocker), how does omeprazole differ mechanistically?
ABlocks histamine Hβ receptors reversibly
BIrreversibly inhibits HβΊ/KβΊ-ATPase pump
CBlocks Mβ muscarinic receptors
DNeutralizes gastric acid directly
EEnhances mucus production
B. PPIs irreversibly block the final step (HβΊ/KβΊ-ATPase), making them more potent than Hβ blockers (reversible, upstream block). Ranitidine blocks Hβ (A), not the pump. Pirenzepine blocks Mβ (C). Antacids neutralize directly (D). Misoprostol enhances mucus (E).
MCQ 2 β Cimetidine Side Effect
A 55-year-old man on cimetidine for peptic ulcer disease develops gynecomastia and erectile dysfunction. What is the mechanism?
ACYP450 inhibition + androgen receptor blockade
BDirect testosterone suppression
CEstrogen receptor upregulation
DProlactin elevation
EReduced hepatic testosterone metabolism
A. Cimetidine is a potent CYP inhibitor (βdrug metabolism) AND blocks androgen receptors (antiandrogen). Both effects β gynecomastia, impotence, erectile dysfunction. Ranitidine/famotidine don't have these side effects. Metoclopramide causes hyperprolactinemia (D), not cimetidine.
MCQ 3 β Sucralfate Timing
A patient on sucralfate for ulcer protection is also prescribed omeprazole. What is the key consideration?
AGive both drugs together for maximum effect
BSeparate dosing β sucralfate requires acidic pH to work
CSucralfate reduces PPI absorption by 50%
DPPIs are contraindicated with sucralfate
ENo interaction β both can be dosed simultaneously
B. Sucralfate polymerizes ONLY in acidic environment. If PPIs suppress acid, sucralfate cannot activate β ineffective. Give sucralfate 1 hour before meals (separate timing from PPI). Same issue with Hβ blockers.
MCQ 4 β Misoprostol in Pregnancy
A 32-year-old woman with NSAIDinduced ulcers is prescribed misoprostol for cytoprotection. What is the critical contraindication?
AIncreases gastric acid secretion
BTeratogenic and abortifacient β pregnancy contraindicated
CCauses severe diarrhea
DInteracts with NSAIDs
EReduces NSAID efficacy
B. Misoprostol is a PGEβ analog that stimulates uterine contractions β abortifacient. Absolutely contraindicated in pregnancy. Also used therapeutically for medical abortion. Diarrhea (C) is a common SE but not the critical issue. Women of childbearing age must use contraception.
MCQ 5 β Ondansetron vs. Metoclopramide
A 45-year-old receives chemotherapy. Which antiemetic blocks 5-HTβ and is ideal for acute chemo-induced nausea?
AOndansetron
BMetoclopramide
CScopolamine
DProchlorperazine
EDomperidone
A. Ondansetron (5-HTβ antagonist) is the gold standard for chemo-induced nausea β blocks serotonin-mediated emesis from GI damage. Metoclopramide is a Dβ antagonist (different mechanism, CNS EPS risk). Scopolamine = motion sickness. Prochlorperazine = older antipsychotic antiemetic.
MCQ 6 β Loperamide BBB Crossing
Why is loperamide safe OTC while diphenoxylate is prescription-only?
ALoperamide is a P-glycoprotein substrate β does NOT cross BBB at therapeutic doses
BLoperamide has no CNS effects
CDiphenoxylate is more lipophilic
DLoperamide is not an opioid
EDiphenoxylate crosses the BBB
A. Loperamide is a ΞΌ-opioid but substrate of P-glycoprotein (efflux transporter) β does NOT cross BBB at therapeutic doses β minimal CNS effects, safe OTC. Diphenoxylate + atropine is prescription to deter abuse (atropine deters overdose). Both are ΞΌ-agonists, but loperamide has the BBB protection.
MCQ 7 β ORS Mechanism in Cholera
Why does oral rehydration solution (ORS) work despite cholera toxin causing massive secretory diarrhea?
AORS neutralizes cholera toxin
BORS blocks cAMP production
CSGLTβ co-transporter still works β drives NaβΊ+glucose absorption independent of cAMP
DORS contains antimicrobial agents
EORS increases intestinal peristalsis
C. Cholera toxin β βcAMP β Clβ» secretion + water loss. But SGLTβ (NaβΊ-glucose cotransporter) is NOT cAMP-regulated β still absorbs NaβΊ + glucose β water follows osmotically. ORS (2% glucose + 90 mEq NaβΊ) exploits this pathway β life-saving. Does NOT neutralize toxin or block cAMP.
MCQ 8 β Quadruple vs. Triple H. pylori
In regions with high clarithromycin resistance, what is the preferred first-line H. pylori regimen?
APPI + Clarithromycin + Amoxicillin
BPPI + Bismuth + Metronidazole + Tetracycline
CPPI + Metronidazole + Clarithromycin
DBismuth + Tetracycline monotherapy
EPPI monotherapy
B. Quadruple PBMT (PPI + Bismuth + Metronidazole + Tetracycline) is now preferred empirically due to rising clarithromycin resistance. Triple therapy (PPI + Clarithromycin + Amoxicillin) was standard but is outdated in many regions. Confirm eradication 4+ weeks post-treatment.
MCQ 9 β Metoclopramide EPS
A 62-year-old on metoclopramide for gastroparesis develops tremor, rigidity, and bradykinesia. What is the mechanism?
A5-HTβ agonism in basal ganglia
BDβ antagonism in CNS (crosses BBB) β Parkinsonian symptoms
CAnticholinergic effects
DGABA antagonism
ESerotonin syndrome
B. Metoclopramide crosses BBB β Dβ antagonism in basal ganglia β extrapyramidal side effects, Parkinsonian features, tardive dyskinesia with chronic use. Contraindicated in Parkinson's disease. Ondansetron does NOT cross BBB significantly, so fewer CNS effects.
MCQ 10 β Infliximab Pre-screening
Before starting infliximab for Crohn's disease, what mandatory screening is required?
AHLA-B allele testing
BTuberculosis screening + hepatitis B screening
CHIV testing
DCardiac ejection fraction
EComplete metabolic panel
B. Anti-TNF agents (infliximab, adalimumab) carry risk of TB reactivation and HBV reactivation β mandatory TB screen (PPD/IGRA) and HBsAg/anti-HBc before start. Must also warn of lymphoma, fungal infections, CHF exacerbation, demyelination. HLA-B testing is for abacavir (HIV drug), not TNF inhibitors.
MCQ 11 β PPI Long-term Complications
A 70-year-old on chronic PPI therapy presents with a hip fracture from minor trauma. What is the mechanism of increased fracture risk?
Aβcalcium and βmagnesium absorption β osteomalacia/osteoporosis
BDirect inhibition of osteoblasts
CVitamin K deficiency
DIncreased parathyroid hormone
EDirect calcitriol antagonism
A. Long-term PPIs β βgastric acid β βCaΒ²βΊ/MgΒ²βΊ absorption (need acid for ionization) β osteomalacia/osteoporosis β fractures. Also βBββ, βKβΊ. Monitor elderly on chronic PPIs; consider calcium/Mg supplementation. Secondary hyperparathyroidism (βPTH) may occur.
Full Clinical Vignettes: 8β10 patient presentations with comprehensive clinical context.
Vignette 1 β NSAID Gastritis + Prophylaxis
Hx: 68-year-old with osteoarthritis on high-dose indomethacin develops epigastric pain. Endoscopy shows acute gastric erosion. Q: Which drug would be most appropriate for NSAID-induced ulcer prophylaxis?
ACimetidine (less expensive)
BMisoprostol (PGEβ analog β βmucus, βHCOββ»)
B. Misoprostol is indicated specifically for NSAID-induced ulcer prevention in high-risk patients (elderly, prior ulcer history). It directly stimulates protective mechanisms (mucus, HCOββ», blood flow) that NSAIDs inhibit. PPIs also effective but misoprostol is most directly indicated. Contraception required (teratogenic).
Vignette 2 β H. pylori Eradication Failure
Hx: 52-year-old from Southeast Asia with confirmed H. pylori PUD. Tried triple therapy (PPI + clarithromycin + amoxicillin) 2 months ago; urea breath test now positive (NOT eradicated). Q: What is the next regimen?
B. Failure after triple therapy β likely clarithromycin resistance. Quadruple PBMT (PPI + Bismuth + Metronidazole + Tetracycline) is the empiric next step, covering resistant strains. Repeat eradication test 4+ weeks post-treatment. Bismuth/tetracycline avoid clarithromycin reliance.
Vignette 3 β Hepatic Encephalopathy + Lactulose
Hx: 61-year-old with cirrhosis + ascites develops confusion and asterixis. Serum ammonia 180 Β΅mol/L (high). Q: Which medication would both treat acute encephalopathy AND reduce ammonia?
B. Lactulose is first-line: nonabsorbable disaccharide β bacterial fermentation β lactic acid βpH β protonates NHβ to NHββΊ (trapped, not absorbed) β osmotic diarrhea helps washout. Both reduces ammonia + causes "therapeutic" diarrhea. Effective prophylaxis + acute therapy. PPIs have minor role; rifaxomicin is adjunct.
Vignette 4 β Cimetidine Gynecomastia
Hx: 51-year-old on cimetidine for peptic ulcer develops tender bilateral breast enlargement + erectile dysfunction over 6 weeks. Testosterone and LH normal. Q: What mechanism explains both symptoms?
B. Cimetidine is dual-action: (1) CYP450 inhibitor β βclearance of endogenous hormones, (2) antiandrogen (blocks androgen receptors). Combined effect β relative estrogen dominance β gynecomastia + impotence. Normal testosterone because the problem is androgen receptor blockade, not hormone production. Switch to famotidine (no antiandrogen effect).
Vignette 5 β Chemo-Induced Nausea Management
Hx: 47-year-old receiving cisplatin chemotherapy suffers severe nausea/vomiting on day 2β3 post-infusion. Standard ondansetron pre-med (5-HTβ) + dexamethasone given but delayed nausea persists. Q: Which additional antiemetic targets delayed emesis?
AMore ondansetron
BAprepitant (NKβ antagonist β standard for delayed)
CMetoclopramide monotherapy
DScopolamine patch
EDiphenhydramine alone
B. Aprepitant (NKβ antagonist) is gold standard for delayed chemo-induced nausea (days 2β3, not acute). Ondansetron + dexamethasone cover acute phase; aprepitant covers delayed. Different pathophysiology: delayed involves substance P + NKβ pathway, not pure 5-HTβ. Often given 3 days post-chemo as part of triple-agent regimen.
Vignette 6 β Motion Sickness Prophylaxis
Hx: 34-year-old preparing for a long ocean cruise knows from experience he develops severe motion sickness. Q: Which agent targets the vestibular pathway most effectively?
AOndansetron (more for chemo/post-op)
BMetoclopramide (prokinetic, not vestibular)
CScopolamine patch (Mβ antagonist in vestibular nucleus)
DAprepitant (NKβ, for delayed chemo)
EBismuth subsalicylate
C. Motion sickness involves vestibular apparatus (Hβ, Mβ receptors) β NTS. Scopolamine (transdermal Mβ antagonist) is ideal for motion sickness prevention (can apply patch before travel). Also dimenhydrinate/meclizine (Hβ antihistamine) work well. Ondansetron is for chemo/blood-borne toxins (CTZ pathway), not vestibular.
Vignette 7 β Crohn's Flare + Biologics
Hx: 28-year-old with Crohn's disease refractory to 5-ASA + corticosteroids develops fever, RLQ pain, diarrhea. CT shows transmural inflammation with fistulas. Q: Which biologic is indicated for this Crohn's flare?
B. Crohn's = transmural + skip lesions + fistulizing β anti-TNF (infliximab/adalimumab) is preferred first-line biologic. UC = mucosal + continuous β 5-ASA first-line biologic (vedolizumab, ustekinumab are newer options for both, but anti-TNF best for Crohn's phenotype). Must screen TB/HBV before starting.
Vignette 8 β Loperamide vs. Flagyl in C. difficile
Hx: 71-year-old hospitalized with diarrhea; C. difficile toxin positive. Resident orders loperamide for symptom control. Q: Why is loperamide contraindicated here?
ALoperamide is ineffective against C. difficile
BRisk of toxic megacolon (βperistalsis traps toxins)
CLoperamide causes diarrhea (paradoxical)
DInteraction with metronidazole
EAllergic cross-reactivity
B. Antiperistaltic agents (loperamide, diphenoxylate) are contraindicated in C. difficile-associated diarrhea β βmotility traps toxins in colon β toxic megacolon, perforation, mortality β. Use metronidazole or vancomycin, NOT antidiarrheals. Same caution in bloody diarrhea (shigella, salmonella, etc.).
Step 1 Traps: Classic confusions and second-order thinking mistakes.
Trap 1
"Cimetidine and ranitidine are interchangeable Hβ blockers."
FALSE. While both are Hβ blockers, cimetidine has serious side effects: CYP450 inhibition (βdrug interactions) + antiandrogen (gynecomastia, impotence). Ranitidine, famotidine, nizatidine do NOT. Cimetidine is largely obsolete for this reason.
Trap 2
"You can give PPIs and sucralfate at the same time for maximum ulcer protection."
FALSE. Sucralfate requires ACIDIC pH to polymerize and form protective gel. PPIs suppress acid β sucralfate cannot activate. Must separate dosing (sucralfate β₯1 hour before PPI). Same issue with Hβ blockers.
Trap 3
"Misoprostol is safe in pregnancy to prevent NSAID-induced ulcers."
FALSE. Misoprostol is TERATOGENIC and ABORTIFACIENT β pregnancy is absolute contraindication. Women of childbearing age on misoprostol must use reliable contraception. Actually used for medical abortion. Use alternative (PPI instead).
Trap 4
"Metoclopramide is an antiemetic with no CNS side effects."
FALSE. Metoclopramide is Dβ antagonist that CROSSES BBB β extrapyramidal effects (tremor, rigidity, dystonia), tardive dyskinesia, parkinsonism. Contraindicated in Parkinson's disease. Ondansetron does NOT cross BBB significantly (safer CNS profile).
Trap 5
"Ondansetron is the best antiemetic for all causes of nausea."
FALSE. Ondansetron blocks 5-HTβ (effective for chemo, post-op, vagal GI input). DOES NOT work for motion sickness (vestibular pathway = Hβ/Mβ). Use scopolamine or antihistamine for motion sickness. Aprepitant (NKβ) for delayed chemo nausea.
Trap 6
"Loperamide carries high abuse potential because it crosses the BBB like other opioids."
FALSE. Loperamide is a ΞΌ-opioid but P-glycoprotein substrate β does NOT cross BBB at therapeutic doses β minimal CNS effects β safe OTC. Diphenoxylate DOES cross BBB better (hence combined with atropine to deter abuse). This difference is KEY to their regulatory status.
Trap 7
"Antidiarrheals like loperamide are beneficial in C. difficile-associated diarrhea."
FALSE. Antiperistaltic agents are CONTRAINDICATED in C. difficile (and bloody diarrhea) β βmotility traps toxins β toxic megacolon, perforation, mortality β. Use antibiotics (metronidazole, vancomycin), NOT motility slowers. Same caution applies to invasive bacterial diarrhea.
Trap 8
"5-ASA is the first-line biologic for both Crohn's and UC."
MISLEADING. 5-ASA is first-line medical therapy for UC (mucosal disease). Crohn's (transmural) often needs anti-TNF biologic earlier. Also: 5-ASA is not technically a "biologic" β biologics = antibodies/cytokine antagonists. Terminology matters on Step 1.
Trap 9
"Infliximab (chimeric) and adalimumab (fully human) have identical immunogenicity."
FALSE. Adalimumab (fully human) is LESS immunogenic than infliximab (chimeric = mouse/human hybrid). Less immunogenicity = less anti-drug antibodies = more durable effect. Both still risk TB reactivation, fungal infections, lymphoma, CHF. Pre-treatment TB/HBV screening mandatory for both.
Antacid Comparison
Drug
Onset
Mechanism
Main SE
Notes
CaCOβ
Rapid (5 min)
Neutralizes HCl
Rebound acid, milk-alkali syndrome
Avoid chronic use
Mg(OH)β
Fast
Osmotic laxative
Diarrhea; Mg toxicity in renal failure
Monitor MgΒ²βΊ levels
Al(OH)β
Slow
Binds phosphate
Constipation, hypophosphatemia, osteomalacia
Avoid in renal failure
NaHCOβ
Rapid
Neutralizes HCl
Systemic alkalosis, NaβΊ overload
Avoid in CHF, HTN
Key: Antacids are fast but have significant SEs. PPIs/Hβ blockers preferred for PUD/GERD. Combine antacids cautiously (e.g., Mg + Al in ratio to avoid laxation/constipation).
Hβ Blockers vs. PPIs
Property
Hβ Blockers
PPIs
P-CABs
Target
Hβ receptor (reversible)
HβΊ/KβΊ-ATPase (irreversible)
HβΊ/KβΊ-ATPase (reversible, KβΊ-competitive)
Potency
Moderate
High (most potent)
Very high, faster onset
Onset
Fast
Slow (prodrug, needs activation)
Faster than PPIs
Duration
Short (4β6 hrs)
Long (3β5 days after stop)
Intermediate
Cimetidine
CYP inhibitor, antiandrogen
β
β
Common SEs
Gynecomastia (cimetidine only)
βBββ/Ca/Mg, C. diff, hip fracture
Fewer long-term SEs
Clinical pearl: PPIs preferred for ZES, severe GERD. Hβ blockers less potent but fewer interactions (except cimetidine). P-CABs (vonoprazan) emerging alternative in Japan/EU.